**Genentech to Invest $700 Million in New North Carolina Manufacturing Facility**
Genentech, a member of the Roche Group, has announced plans to invest over $700 million in a new 700,000-square-foot drug manufacturing facility in Holly Springs, North Carolina. The facility will be a key addition to Genentech’s global manufacturing network, reinforcing the company’s strategy to expand its capabilities in the United States.
Ashley Magargee of Genentech commented, “Our new facility near Raleigh, North Carolina—an established biopharmaceutical talent hub—will serve as an important new setting within our manufacturing network to help deliver on the promise of our company’s life-changing science and industry-leading pipeline.”
The development is expected to create more than 400 high-wage manufacturing jobs once operational and to support over 1,500 construction jobs during the site’s development phase. The facility will focus on supporting Roche and Genentech’s future portfolio of next-generation obesity medicines. The company also noted that this initial investment could expand further depending on future business needs and the overall U.S. policy environment.
Currently, Roche and Genentech maintain a significant presence in the United States, with 13 manufacturing and 15 research and development sites across their Pharmaceutical and Diagnostics Divisions. The company employs about 25,000 people at 24 locations across eight states.
